Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Drug company (FDA labeler)

United Therapeutics Corporation

NDC labeler code: 66302

What is a labeler?

The company whose name is on the package and in the FDA’s National Drug Code (NDC) Directory. It may make the medicine itself or sell medicine made by another company. The first part of every NDC code identifies the labeler.

Official FDA data only

Products, approvals and recalls come from the FDA (NDC Directory, Drugs@FDA, enforcement reports). Recalls are linked to this company by the NDC labeler code on the recalled product.

Questions about your medicine: ask your doctor or pharmacist. In an emergency, call 911.

At a glance

24Products (NDC)

Prescription medicines

FDA applications for these products

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
  • BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.
ApprovedApplicationMedicineSponsor
May 23, 2022NDA214324 Treprostinil
TYVASO DPI
United Therap
March 10, 2015BLA125516 Dinutuximab
UNITUXIN
United Therap
December 20, 2013NDA203496 Treprostinil
ORENITRAM
United Therap
July 30, 2009NDA022387 Treprostinil
TYVASO
United Therap
May 22, 2009NDA022332 Tadalafil
ADCIRCA
Eli Lilly Co
May 21, 2002NDA021272 Treprostinil, Water
REMODULIN
United Therap

The sponsor is the company that holds the FDA application; it can differ from the labeler.

Recall timeline

2018

  1. August 14, 2018 · Class III · Terminated · D-1188-2018 · Treprostinil

    Defective Delivery System: Water ingress through the lower water cup sensor of the device.

    Tyvaso Inhalation System Patient a) Starter Kit with TYVASO (treprostinil) Inhalation Solution. Treprostinil 1.74 mg/2.9 mL (0.6 mg/mL) (NDC 66302-206-01) b) TD-300/A Replacement Device Kit Material Number RTP3099 RX Onl

What do the recall classes mean?

Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).

Sources

  1. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  2. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026

FDA Enforcement Report search → · Report an error →